Abstracts tagged "systemic sclerosis and treatment options"

Abstract Number: 2673 • 2017 ACR/ARHP Annual Meeting
Real-Life Treatment Strategies for Systemic Sclerosis According to Experts
Andreu Fernández-Codina^1,2, Kyle M Walker³ and Janet E. Pope⁴, ¹Rheumatology, University of Western Ontario, London, ON, Canada, ²Systemic Autoimmune Diseases, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³Dept. of Medicine, Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁴University of Western Ontario, London, ON, Canada
Background/Purpose:Second line treatment options for Systemic Sclerosis (SSc) are limited, and scarce data are available for choosing the order of treatment. The aim of this…
Abstract Number: 1678 • 2014 ACR/ARHP Annual Meeting
Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort
Matthew R. Lammi¹, Lesley Ann Saketkoo², Stephen C. Mathai³, Robyn T. Domsic⁴, Christine M. Bojanowski⁵, Virginia D. Steen⁶, Daniel E. Furst⁷ and Pharos Investigators⁸, ¹Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³Medicine, Johns Hopkins University, Baltimore, MD, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Internal Medicine and Pediatrics, LSU Health Sciences Center, New Orleans, LA, ⁶Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁷University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁸Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc). Although medications have improved their prognosis, optimal therapy remains undefined.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].